People: Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

21 Feb 2020
Change (% chg)

$-0.82 (-8.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Shepard, Jay 

Mr. Jay P. Shepard serves as Chairman of the Board of the Company. Mr. Shepard was an Executive Partner at Sofinnova Ventures, or Sofinnova, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. Mr. Shepard previously served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. in November 2012, from January 2010 to November 2012. From December 2005 to October 2007, Mr. Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders that was acquired by Amgen in July 2007. Mr. Shepard has served on the boards of directors of numerous public and private companies, including Ilypsa, Inc., Relypsa, Inc., Intermune, Inc., Bullet Biotechnology, Inc., Marinus Pharmaceuticals, Inc., and Durect Corporation. Currently, Mr. Shepard serves on the board of directors of Esperion Therapeutics, Inc., a pharmaceutical company, and of the Christopher & Dana Reeve Foundation.

Basic Compensation

Total Annual Compensation, USD 810,264
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 8,024
Fiscal Year Total, USD 818,288

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --